Key clinical point: Almost 80% of the effect of tofacitinib treatment on health-related quality of life (HRQoL ) is primarily mediated by improvement in itch and Physician’s Global Assessment of psoriasis (PGA-PsO).
Major finding: Overall, 82.3% of the effect of tofacitinib on HRQoL as measured by the Dermatology Life Quality Index was contributed by improvement in itch score ( P < .0001) and 17.7% was attributed to improvement in PGA-PsO score ( P = 0.0006).
Study details: Findings are from a post hoc analysis of phase 3 trials OPAL Broaden and OPAL Beyond including 468 patients with active psoriatic arthritis ( PsA), randomly assigned to tofacitinib (5 mg or 10 mg twice a day), adalimumab 40 mg (only in OPAL Broaden), or placebo.
Disclosures: This study was funded by Pfizer. The authors declared receiving grants or serving as consultants for several pharmaceutical companies, including Pfizer. Four authors declared being employees and stockholders of Pfizer.
Source: Taylor PC et al. J Clin Med. 2021 (Sep 9);10(18):4081. doi: 10.3390/jcm10184081.